10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
PFIZER INC | |||
Ticker: PFE Fiscal Year: 2014 | |||
Consolidated Statements of Income | |||
Period Ending Dec 31, 2014 10-K (Filed: Feb 27, 2015) | |||
| (In Millions) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2012 | |
| Revenues | $ 49,605 | 51,584 | 54,657 |
| Costs and expenses: | |||
| Cost of sales(a) | 9,577 | 9,586 | 9,821 |
| Selling, informational and administrative expenses(a) | 14,097 | 14,355 [1] | 15,171 |
| Research and development expenses(a) | 8,393 | 6,678 | 7,482 |
| Amortization of intangible assets | 4,039 | 4,599 | 5,109 |
| Restructuring charges and certain acquisition-related costs | 250 | 1,182 | 1,810 |
| Other (income)/deductionsnet | 1,009 | (532) | 4,022 |
| Income from continuing operations before provision for taxes on income | 12,240 [2] | 15,716 | 11,242 |
| Provision for taxes on income | 3,120 | 4,306 | 2,221 |
| Income from continuing operations | 9,119 | 11,410 | 9,021 |
| Discontinued operations: | |||
| Income from discontinued operationsnet of tax | (6) | 308 | 794 |
| Gain on disposal of discontinued operationsnet of tax | 55 [3] | 10,354 | 4,783 |
| Discontinued operationsnet of tax | 48 | 10,662 | 5,577 |
| Net income before allocation to noncontrolling interests | 9,168 | 22,072 | 14,598 |
| Less: Net income attributable to noncontrolling interests | 32 | 69 | 28 |
| Net income attributable to Pfizer Inc. | 9,135 | 22,003 | 14,570 [4] |
| Earnings per common sharebasic: | |||
| Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) | 1.43 | 1.67 | 1.21 |
| Discontinued operationsnet of tax (in dollars per share) | 0.01 | 1.56 | 0.75 |
| Net income attributable to Pfizer Inc. common shareholders (in dollars per share) | 1.44 | 3.23 | 1.96 |
| Earnings per common sharediluted: | |||
| Income from continuing operations attributable to Pfizer Inc. common shareholders | 1.41 | 1.65 | 1.20 |
| Discontinued operationsnet of tax | 0.01 | 1.54 | 0.74 |
| Net income attributable to Pfizer Inc. common shareholders | 1.42 | 3.19 | 1.94 |
| Weighted-average sharesbasic | 6,346 | 6,813 | 7,442 |
| Weighted-average sharesdiluted | 6,424 | 6,895 | 7,508 |
| Cash dividends paid per common share (in dollars per share) | 1.04 | 0.96 | 0.88 |
| [1] Exclusive of amortization of intangible assets, except as disclosed in Note 1K. Basis of Presentation and Significant Accounting Policies: Amortization of Intangible Assets, Depreciation and Certain Long-Lived Assets. | |||
| [2] Income from continuing operations before provision for taxes on income. | |||
| [3] Includes post-close adjustments for the periods subsequent to disposal. | Includes the Animal Health (Zoetis) business through June 24, 2013, the date of disposal, and the Nutrition business through November 30, 2012, the date of disposal. | |||
| [4] Amounts may not add due to rounding. | |||
| External Links | |
| PFIZER INC (PFE) Fiscal Year 2014 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |